Omeros Corporation

Omeros Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of small-molecule and protein therapeutics. Its primary focus is on creating treatments for disorders related to inflammation, complement-mediated diseases, and central nervous system conditions. A noteworthy product from Omeros is its commercial drug, Omidria, used during cataract surgery or lens replacement procedures to maintain pupil size and reduce postoperative pain. The company leverages its proprietary platforms, such as its G protein-coupled receptor (GPCR) program, to further its research and development efforts. Omeros targets significant segments in the healthcare sector, impacting both speciality pharmaceuticals and biotechnology industries. Headquartered in Seattle, Washington, the corporation plays a critical role in addressing unmet medical needs through innovative therapies, contributing to ongoing advances in medical treatment and patient care.